Saturday, July 07, 2018 9:31:10 AM
Ok folks. Time to take a deep breath and understand what the Cantor agreement actually means for Anavex.
I imagine most here probably have me in the “basher” category. I prefer to view myself in the “let’s get this right” category. So let’s get this right then.
The intent to have the ability to raise $100 million dollars was actually announced way back in 2015.
“As filed with the Securities and Exchange Commission on October 23, 2015”
PROSPECTUS
Anavex Life Sciences Corp.
$100,000,000 of Shares of Common Stock
https://www.sec.gov/Archives/edgar/data/1314052/000161577415003018/s102056_forms3.htm
Now, of that $100 million, $50 million was authorized to be sold to LPC.
“$50,000,000 of Shares of Common Stock and 269,397 Shares of Common Stock Offered by Selling Security Holder”
Now here is an important part...
“At March 31, 2018, an amount of $16,683,157 remained available under the 2015 Purchase Agreement”
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=12746138-964-109326&type=sect&TabIndex=2&companyid=660924&ppu=%252fdefault.aspx%253fcompanyid%253d660924
So in three years the $50 million authorized dilution was still not fully implemented.
Most here seem to think this new Cantor announcement is a negative development and means $50 million of dilution is happening “right now”, but as illustrated above, it could be implemented over a number of years.
I personally would put the Cantor announcement in the positive development category. Here’s why:
Anavex management still retains the ability to determine when and how much dilution they allow to happen. This is not an announcement of $50 million of dilution. It’s an announcement that Anavex now has access to $50 million dollars in capital, if and when they want to access it.
We have entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald, pursuant to which we may issue and sell up to $50 million shares of our common stock, $0.01 par value per share, through Cantor Fitzgerald, acting as sales agent”
I’ve been attempting to get folks to understand for months now that the LPC agreement was an ELOC and not an ATM.
Here is the difference. Under this agreement Cantor does not purchase the shares from Anavex and then resell them into the market for a profit like LPC does. Cantor would instead sell shares for Anavex directly into the market on Anavex’s behalf . A real life ATM!!!
“Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald may sell our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market or any other existing trading market for our common stock. We or Cantor Fitzgerald may suspend the offering of our common stock upon notice and subject to other conditions.”
http://secfilings.nasdaq.com/efxapi/EFX_dll/EDGARpro.dll?FetchFilingHTML1?ID=12851983&SessionID=zQJoUxvsotMLr5X#S111202_424B5_HTM_A_001
Instead of making money in a way that invites price manipulation like LPC, here is how Cantor get paid.
“We will pay Cantor Fitzgerald in cash, upon each sale of our common stock pursuant to the Sales Agreement, a commission in an amount equal to 3.0% of the aggregate gross proceeds from each sale of our common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cantor Fitzgerald for certain specified expenses, in an aggregate amount not exceeding $50,000, including the fees and disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor Fitzgerald under the terms of the Sales Agreement, will be approximately $90,000.
Think of it like this if it helps.
Let’s say you want to sell your house.
LPC would buy your house directly from you and try to make a profit by selling it to someone else for a profit.
Cantor on the other hand would be like a Realtor. They would sell your house at the highest price possible to someone else and make a 3% commission on the sales price.
If you wanted to get the most money for you house which method would you choose?
I hope the choice and the reasoning behind the choice are obvious!
What actually happened is that Anavex has cut out the “payday lender” type LPC agreement and replaced it with a much more preferable way to Capital access when they deem it appropriate.
In reality since $16 million is still left from the LPC agreement this new announcement could only represent $33 million in additional expected dilution instead of $50 million if they only use Cantor from here on.
Hope this helps. There’s more to be said, but time for a break.
I imagine most here probably have me in the “basher” category. I prefer to view myself in the “let’s get this right” category. So let’s get this right then.
The intent to have the ability to raise $100 million dollars was actually announced way back in 2015.
“As filed with the Securities and Exchange Commission on October 23, 2015”
PROSPECTUS
Anavex Life Sciences Corp.
$100,000,000 of Shares of Common Stock
https://www.sec.gov/Archives/edgar/data/1314052/000161577415003018/s102056_forms3.htm
Now, of that $100 million, $50 million was authorized to be sold to LPC.
“$50,000,000 of Shares of Common Stock and 269,397 Shares of Common Stock Offered by Selling Security Holder”
Now here is an important part...
“At March 31, 2018, an amount of $16,683,157 remained available under the 2015 Purchase Agreement”
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=12746138-964-109326&type=sect&TabIndex=2&companyid=660924&ppu=%252fdefault.aspx%253fcompanyid%253d660924
So in three years the $50 million authorized dilution was still not fully implemented.
Most here seem to think this new Cantor announcement is a negative development and means $50 million of dilution is happening “right now”, but as illustrated above, it could be implemented over a number of years.
I personally would put the Cantor announcement in the positive development category. Here’s why:
Anavex management still retains the ability to determine when and how much dilution they allow to happen. This is not an announcement of $50 million of dilution. It’s an announcement that Anavex now has access to $50 million dollars in capital, if and when they want to access it.
We have entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald, pursuant to which we may issue and sell up to $50 million shares of our common stock, $0.01 par value per share, through Cantor Fitzgerald, acting as sales agent”
I’ve been attempting to get folks to understand for months now that the LPC agreement was an ELOC and not an ATM.
Here is the difference. Under this agreement Cantor does not purchase the shares from Anavex and then resell them into the market for a profit like LPC does. Cantor would instead sell shares for Anavex directly into the market on Anavex’s behalf . A real life ATM!!!
“Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald may sell our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market or any other existing trading market for our common stock. We or Cantor Fitzgerald may suspend the offering of our common stock upon notice and subject to other conditions.”
http://secfilings.nasdaq.com/efxapi/EFX_dll/EDGARpro.dll?FetchFilingHTML1?ID=12851983&SessionID=zQJoUxvsotMLr5X#S111202_424B5_HTM_A_001
Instead of making money in a way that invites price manipulation like LPC, here is how Cantor get paid.
“We will pay Cantor Fitzgerald in cash, upon each sale of our common stock pursuant to the Sales Agreement, a commission in an amount equal to 3.0% of the aggregate gross proceeds from each sale of our common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cantor Fitzgerald for certain specified expenses, in an aggregate amount not exceeding $50,000, including the fees and disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor Fitzgerald under the terms of the Sales Agreement, will be approximately $90,000.
Think of it like this if it helps.
Let’s say you want to sell your house.
LPC would buy your house directly from you and try to make a profit by selling it to someone else for a profit.
Cantor on the other hand would be like a Realtor. They would sell your house at the highest price possible to someone else and make a 3% commission on the sales price.
If you wanted to get the most money for you house which method would you choose?
I hope the choice and the reasoning behind the choice are obvious!
What actually happened is that Anavex has cut out the “payday lender” type LPC agreement and replaced it with a much more preferable way to Capital access when they deem it appropriate.
In reality since $16 million is still left from the LPC agreement this new announcement could only represent $33 million in additional expected dilution instead of $50 million if they only use Cantor from here on.
Hope this helps. There’s more to be said, but time for a break.
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM

